OBJECTIVE To sort out reform policy for basic medical insurance designated retail pharmacy （referred to as designated retail pharmacy） in China， and to provide reference for the improvement of the policy under the new situation of mutual- aid mechanism for covering outpatient bills. METHODS The policy texts on designated retail pharmacies issued by ministries and commissions of the State Council and departments directly under the State Council were collected from December 1998 to June 2023. The content analysis and social network analysis were adopted to construct a three-dimensional analytical framework based on the policy subject， the policy tool， and the policy process， in order to quantitatively analyze the policies on reforming designated retail pharmacies. RESULTS & CONCLUSIONS The reform policy of designated retail pharmacies can be roughly divided into three stages： germination， exploration and development， and in-depth promotion. The use of policy tools is dominated by environment-oriented tools， and the cooperation network of policy subjects presents a “head-body-tail” chain structure. With the advancement of policy reforms， the number of policy subjects showed a trend of decline followed by growth， the number of policy documents showed an upward trend， emphasizing the use of tools such as the construction of the pharmacist system， the flow of prescriptions， the payment of medical insurance， and the management of “dual-channels” and “outpatient co-ordination”. It is suggested that in terms of policy formulation， all policy subjects should adhere to top-level design， grasp the characteristics of the stage of policy development， and adjust the use of policy tools according to local and timely conditions； we should also strengthen cooperation and communication， improve policy formulation efficiency， achieve policy coordination， and continuously improve policies for designated retail pharmacies.

Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists(GLP-1RAs)on asthma,which is often comorbid with type 2 diabetes mellitus(T2DM)and obesity.Therefore,we conducted a meta-analysis to assess the association between the administration of glucagon-like peptide-1(GLP-1)receptor-based agonists and the incidence of asthma in patients with T2DM and/or obesity. Methods PubMed,Web of Science,Embase,the Cochrane Central Register of Controlled Trials,and Clinicaltrial.gov were systematically searched from inception to July 2023.Randomized controlled trials(RCTs)of GLP-1 receptor-based agonists(GLP-1RA,GLP-1 based dual and triple receptor agonist)with reports of asthma events were included.Outcomes were computed as risk ratios(RR)using a fixed-effects model. Results Overall,39 RCTs with a total of 85,755 participants were included.Compared to non-GLP-1 receptor-based agonist users,a trend of reduced risk of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments,although the difference was not statistically significant[RR=0.91,95%confidence interval(CI):0.68 to 1.24].Further Subgroup analyses indicated that the use of light-molecular-weight GLP-1RAs might be associated with a reduced the risk of asthma when compared with non-users(RR=0.65,95%CI:0.43 to 0.99,P=0.043).We also performed sensitivity analyses for participant characteristics,study design,drug structure,duration of action,and drug subtypes.However,no significant associations were observed. Conclusion Compared with non-users,a modest reduction in the incidence of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments.Further investigations are warranted to assess the association between GLP-1 receptor-based agonists and the risk of asthma.

OBJECTIVE To explore the pricing methods of multi-indication drugs suitable for China from the economic perspective. METHODS By sorting out the situation and pricing methods of multi-indication drugs in China’s health insurance negotiation in recent years， the experience of typical countries （Sweden， Germany， Britain， Italy， etc.） in the value measurement， access and management of multi-indication drugs were explored with 3 methods， namely， branded pricing， weighted average bidding pricing， and single bidding pricing under the risk sharing agreement. The advantages and disadvantages of the 2 types of multi-indication drug pricing methods， such as single bidding pricing and indication-based pricing， and conditions of use were explored， so as to put forward a pricing method suitable for multi-indication drugs in China. RESULTS＆＆CONCLUSIONS The pricing of multi-indication drugs by single bidding pricing mode has certain disadvantages at this stage， and should be supplemented and improved by agreement pricing. Based on international experience， China can explore a reasonable management mode of drug indications， adopt a pricing mode with agreement pricing as the main mode and multiple pricing modes as the coexisting mode， and promote the development of pharmacoeconomic evaluation and the improvement of drug use information collection mechanism.

OBJECTIVE To analyze the evolution of the focus of Chinese pharmaceutical administration, so as to improving the effectiveness of drug regulation. METHODS Through word frequency and social network analysis, the word cloud and network graph were visualized for the evolution process of Chinese drug regulatory policies, and the different evolutionary characteristic of policies content were analyzed using graph density, clustering coefficient, betweenness centrality, degree centrality and other indicators. RESULTS There were differences in network characteristics in different periods, the overall network connection tended to be tight, the structure tended to be optimized, and the connection between individual network subgroups was gradually complicated. However, the number of subgroups decreased in 2018—2022, and the core nodes were transferred. CONCLUSION In the current special period of “epidemic economy”, it is necessary to broaden the special policy areas and strengthen the coordination and intersection of policy concerns.

OBJECT IVE To provide reference for relevant decision-makers to formulate policies to guide the transfer of pharmaceutical industry. METHODS Using the statistical data from 2000 to 2019，taking industrial transfer index as index ，on the basis of 4 regions，our country was divided into 8 comprehensive economic areas ：the eastern coastal area ，the southern coastal area，the northern coastal area ，the middle reaches of the Yellow River area ，the middle reaches of the Yangtze River area ，the northeast area ，the southwest area and the northwest area. The regional characteristics and regularity of China ’s pharmaceutical industrial transfer were discussed in terms of space and time. RESULTS & CONCLUSIONS From 2004 to 2019，among the 31 provinces，pharmaceutical industry was transferred in 19 provinces，including Jilin ，Shandong，Henan and Gansu ，accounting for 61.3％；pharmaceutical industry was transferred out in 12 provinces，including Hebei ，Beijing，Xinjiang and Hubei ，accounting for 38.7％. There were 12 provinces whose absolute average values of industrial transfer index were greater than 0.2，indicating that China’s pharmaceutical industry had undergone large-scale migration among provinces ，and the scale of pharmaceutical industrial transfer varied significantly among provinces. From the perspective of regional distribution ，4 pharmaceutical industrial transfer-in centers had been formed in China ，the eastern coastal area ，the northeast area ，the middle reaches of the Yangtze River area and the southern coastal area ；industrial transfer followed the location selection mode from within areas to between areas. From the perspective of time change trend ，there was a phenomenon of gradient deviation in the transfer of pharmaceutical industry in various areas of China ，and there are 5 evolution types ，mainly including “up and down fluctuation ”，“first decrease and then increase”，“first increase and then decrease ”；the transfer of pharmaceutical industry was active in most areas ，and the transfer path remained relatively stable. In some areas ，the roles of transfer-out place and transfer-in place had been exchanged. According to the scale and trend of industrial transfer ，each area should formulate guiding policies to realize the coordinated development of inter-regional pharmaceutical industry.

OBJECTIVE To provide reference for improving resource carrying capacity of pharmaceutical industry and guaranteeing the healthy and sustainable development of pharmaceutical industry of China. METHODS The evaluation system of resource carrying capacity was constructed ，including 4 primary indicators and 17 secondary indicators. The data of above indicators were selected from 31 provinces（autonomous regions and municipalities ）（hereinafter referred to as provinces ）of China during 2013-2020. The index weight and regional relevance were calculated by entropy weight technique for order preference by similarity to ideal solution（TOPSIS）method. RESULTS & CONCLUSIONS The weights of 4 primary indicators were 0.182 0 （industrial scale ），0.349 5（industrial innovation resources ），0.211 5（economic resources ）and 0.257 1（industrial development foundation）. It indicated that industrial innovation resources were the main factor affecting the resource carrying capacity of pharmaceutical industry ，followed by industrial development foundation and economic resources ，and the impact of industrial scale was the least. From 2013 to 2016 and from 2018 to 2020，the average closeness of the pharmaceutical industry in China ’s provinces were 0.259 6，0.267 1，0.253 6，0.249 9，0.250 5，0.248 5 and 0.252 0，respectively. It indicated that the resource carrying capacity of China ’s pharmaceutical industry showed a stable development trend ，but the overall development was in low level. The top 5 regions in terms of closeness of carrying capacity were Jiangsu ，Guangdong，Shandong，Zhejiang and Beijing ；the regions in the bottom 5 were Gansu ，Hainan，Qinghai，Tibet and Ningxia. Overall ，the resource carrying capacity of China ’s pharmaceutical industry showed a gradual decreasing trend from the eastern coastal area to the western inland area. For the provinces with the highest resource carrying capacity of pharmaceutical industry ，further development can be carried out on the basis of maintaining the original carrying capacity ；for the provinces with the middle resource carrying cap acity of p harmaceutical industry ，enhancing the development potential and improving the industrialfoundation are the main methods to improve the resource carrying capacity of pharmaceutical industry ；for the provinces wangjl@126.com with low resource carrying capacity of pharmaceutical industry ， it can be considered to start from their own unique advantages ， make full use of characteri stic industrial resources ，form a characteristic industrial foundation ，actively promote interregional cooperation ，implement regional cluster development and improve the resource carrying capacity of pharmaceutical industry.

OBJECTIVE： To provi de reference for relevant departments to formulate innovation subsidy policies for pharmaceutical enterprises and enterprises to make their own business strategy decisions. METHODS ：The listed enterprises in China ’s pharmaceutical industry listed before 2012 were selected as the sample enterprises. The annual reports of listed enterprises in pharmaceutical industry and related panel data in CSMAR database during 2012-2019 were colected. Referring to related literatures ， multivariate regression model and threshold model were established to investigate the effects of technology innovation investment ability of sample enterprises ，so as to put forward relevant suggestions. RESULTS & CONCLUSIONS ：A total of 57 sample enterprises were included. The panel data of sample enterprises showed that the technology innovation investment of Chinese pharmaceutical enterprises was basically increasing year by year ，but compared with international standards ，the technology innovation investment of Chinese pharmaceutical enterprises still needed to be improved. The results of multiple regression model showed that the technology innovation investment of pharmaceutical enterprises had no significant impact on their current financial performance and the financial performance of the first and second lags （P＞0.05）. The results of threshold model showed that there was a significant single threshold effect between technology innovation investment and financial performance when enterprise size was taken as the threshold variable （P＜0.05）. When the enterprise size was less than the threshold value of 20.986，the enterprise ’s technology innovation investment had a negative impact on its financial performance （P＜0.05）；when the enterprise size was greater than the threshold value of 20.986，the correlation between the enterprise ’s technology innovation investment and financial performance was not significant （P＜0.05）. It is suggested that China ’s pharmaceutical enterprises should carry out technology innovation activities according to their own strength ，and enterprise managers should formulate different innovation development strategies according to the ac tual situation ，enable enterprises to maintain a reasonable capital structure by broadening financing channels ，identify innovation points according to their own ability ，reduce costs and risks ，and innovate R&D modes，so as to promote the transformation and effective utilization of R&D achievements. Government departments should give full play to the guiding role ，encourage pharmaceutical enterprises to maintain the vitality of R&D and innovation and guide the sustainable innovation and healthy development of the pharmaceutical industry.

OBJECTIVE：To study the r elationship between corporate social responsibility ，financing constraints and corporate performance of listed pharmaceutical companies ，so as to provide reference for pharmaceutical enterprises to fulfill their social responsibility in China. METHODS ：Taking 211 A-share listed pharmaceutical companies in China from 2015 to 2018 as samples ， using corporate performance as explained variables ，corporate social responsibility and financing constraints as explanatory variables，asset size ，equity nature ，growth，R&D investment ，marketing investment and annual as control variables ，a multiple regression equation was constructed to study the relationship among corporate social responsibility performance ，financial constraints and corporate performance and put forward the suggestions. RESULTS ：Corporate social responsibility had a significant positive impact on corporate financial performance ；in the promotion of corporate social responsibility on corporate performance ， finacing constratins couldn ’t inhibit the promote function. CONCLUSIONS ：In China ’s pharmaceutical industry ，the awareness of corporate social responsibility needs to be improved ；pharmaceutical enterprises actively perform social responsibility will interactively promote corporate performance. The overall financial constraints faced by Chinese pharmaceutical enterprises are not high，and enterprises which facing financial constraints will better improve their performance by fulfilling corporate social responsibility. It is suggested that the government should promote the legislative process of corporate social responsibility ； pharmaceutical enterprises should enhance the awareness of social responsibility and pay attention to the impact of financing constraints；investors should pay real-time attention to the responsibility information and actual performance of pharmaceutical enterprises.

OBJECTIVE：To su mmarize the achievements and shortcomings of chronic disease management policies in China ， and to provide reference for the formulation and improvement of the policy. METHODS ：Totally 109 documents related to chronic disease management issued by the State Council and various ministries and commissions from 2009 to 2020 were processed by text mining method. PMC index evaluation model of chronic disease management policy was established. Sixteen typical chronic disease management policies were quantitatively evaluated and analyzed by 10 first-level indicators and 40 second-level indicators. RESULTS：Among the 16 policies，10 were of excellent level and 6 were of acceptable level. The average PMC score was 7.243， which was generally acceptable level but still had large room for improvement. By comparing two representative policies ，it was found that the main reasons for the policies with low scores were the lack of long-term development planning ，the absence of “Internet + chronic disease management ”new model and other contents ，and the lack of talent incentive and legal guarantee measures. CONCLUSIONS ：Chronic disease management policy has been improved ，and it can be further improved from the aspects of policy prescription ，policy content and incentive mode.

OBJECTIVE：To provide referen ce for promoting innovation cooperation of pharmaceutical manufacturing industry among regions and building a more perfect and close pharmaceutical innovation cooperation network. METHODS ：Based on China ’s pharmaceutical manufacturing cooperation patent data published by the State Intellectual Property Office ，the main cross-region cooperation patents among 31 provinces，autonomous regions and municipalities in China in 2016 were extracted ；based on literature review ，some hypotheses were put forward about the factors that may affect the cross regional innovation cooperation of Chinese pharmaceutical manufacturing industry. Taking the provincial R&D cooperation intensity as the dependent variable and the above influencing factors as the independent variables ，QAP analysis method was used to establish the model for data analysis. RESULTS & CONCLUSIONS ：Differences in regional economic GDP ，geographic distance ，economic distance ，technical distance，and whether Beijing or Shanghai are involved in the cooperation area all have an impact on cross-regional innovation cooperation in the pharmaceutical manufacturing industry. Large regional economic GDP difference is conducive to promoting cooperation. Developed regions represented by Beijing and Shanghai have strong radiating effects and can significantly promote cooperation. Geographical distance and economic distance have a negative effect on cross-regional innovation cooperation in pharmaceutical manufacturing ，while technological distance has positive effect.